Expert Review of Vaccines

Papers
(The TQCC of Expert Review of Vaccines is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Cost-effectiveness analysis of the use of PNEU-C-21 in adults aged ≥50 years in Canada93
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy85
Monkeypox pandemic containment: does the ACAM2000 vaccine play a role in the current outbreaks?69
Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States61
Indirect protection from rotavirus vaccines: a systematic review55
Adjuvanted-RSVPreF3 vaccine uptake and effectiveness in individuals with COPD: a nationwide Danish cohort study54
Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response53
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic48
Vaccines against chronic Trypanosoma cruzi infection: progress, challenges and future directions45
Response to letter to the editor on a systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children45
Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays44
A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom43
Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China40
Epidemiological shifts in coxsackievirus A-induced hand, foot, and mouth disease in China, 2008–202440
Addressing barriers to and strategies for herpes zoster vaccination in immunocompromised patients in Türkiye: an expert consensus37
Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review37
Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection33
Microarray patches: scratching the surface of vaccine delivery31
Recent advances for the pharmaceutical production of highly attenuated poxviruses as viral vector platforms30
Comparative effectiveness of Omicron XBB 1.5-adapted COVID-19 vaccines: a systematic literature review and network meta-analysis30
The important lessons lurking in the history of meningococcal epidemiology29
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era28
The protective effects of two varicella vaccination strategies: A Bayesian modeling study in two megacities in South China27
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada26
Montanide ISA-51: a promising adjuvant in cancer vaccine immunotherapy26
Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond26
Addressing RSV infection in older adults: implications for public health policy26
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany26
Vaccine hesitancy among 0–6-year-olds’ guardians in Chongqing: a cross-sectional survey revealing how immunization program managers’ robust comprehensive capacity for adverse events following immuniza25
Birth order and influenza vaccination: a comparative study of behaviors and intentions between first-time and second-time Chinese parents25
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion24
Adult respiratory syncytial virus infection and community-acquired pneumonia: pathogenesis, diagnostic challenges and the clinical implications24
Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan24
Adult risk groups for vaccine preventable respiratory infections: an overview of the UK environment24
Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above24
Impact of acellular immunization against pertussis; comparative experience of four countries in North, Central and South America24
The value of public-private collaborative real-world evidence platforms to monitor vaccine performance post authorization: DRIVE - a European initiative24
From burden to benefit: overcoming barriers to immunization in adults, with a focus on respiratory syncytial virus23
Cost-effectiveness of cell-based influenza vaccine in France23
Vaccines preventing neonatal sepsis: focus on Group B Streptococcus , Klebsiella pneumoniae and 23
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis23
Two decades of GSK rotavirus vaccine (RV1): a global analysis to estimate vaccination completion and deaths averted in children under 5 years23
Adapted XBB.1.5 vaccine effectiveness against severe COVID-19 outcomes among immunocompromised persons in 2023–24 in six European countries: a VEBIS-EHR network study22
TAK-003: development of a tetravalent dengue vaccine22
Duration of immunogenicity of high-dose and prolonged-schedule hepatitis B vaccine among patients with chronic kidney disease: A one year follow-up study in China21
Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia21
Reply to: Letter to Editor “Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine”21
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination21
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany21
Modeling the potential public health and economic impact of COVID-19 vaccination strategies using an adapted vaccine in Peru21
Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population20
Modeling the potential public health and economic impact and cost-effectiveness of vaccination strategies using an adapted COVID-19 vaccine in the Dominican Republic20
Narrative shielding and prebunking: a synergistic strategy against vaccine hesitancy in pediatrics20
Novel vaccine platforms for respiratory viruses: a review of licensed vaccines and candidates in late-stage development20
The burden of seasonal influenza: improving vaccination coverage to mitigate morbidity and its impact on healthcare systems19
Anti-neuraminidase immunity in the combat against influenza19
Travelers’ preferences for tick-borne encephalitis vaccination19
Immunogenicity and safety of a live attenuated varicella vaccine in healthy subjects aged between 13 to 55 years: a double-blind, randomized, active-controlled phase III clinical trial in China19
Vaccines against mpox: MVA-BN and LC16m819
Adjuvant system AS01: from mode of action to effective vaccines19
The impact of a pneumococcal vaccination on disease activity in children and adolescents with inflammatory bowel disease: a 2-year prospective study18
Regional molecular epidemiology of dengue and the potential optimization of its control through the use of vaccines. Report of the Arbovirus Committee of the Latin American Society of Pediatric Infect18
Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children18
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months o18
Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease18
Antibody persistence and revaccination recommendations of MenACWY-TT: a review of clinical studies assessing antibody persistence up to 10 years after vaccination18
Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness17
The durability of vaccine-induced protection: an overview17
Preferences and attitudes of healthcare providers towards pneumococcal vaccines for adults in the United States17
Suspended cell lines for inactivated virus vaccine production17
Vaccination policies for dentists and other dental professionals in Europe: a systematic report17
A descriptive review on the real-world impact of Moderna, Inc. COVID-19 vaccines17
Preventing COVID-19 in at-risk populations: moving toward next-generation mRNA-1283 COVID-19 vaccine to address current challenges17
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks16
Changes in serotype distribution and antimicrobial nonsusceptibility of Streptococcus pneumoniae among hospitalized children: Shenzhen, China, 2009–201916
Impact of rotavirus vaccination on diarrheal disease burden of children in South America15
Lessons from a decade of adult vaccine rollout in low- and middle-income countries: a scoping review15
A benefit-cost analysis quantifying the broader socioeconomic value of adult respiratory vaccination programs in Japan15
Estimating the time required to reach HPV vaccination targets across Europe15
Toward an effective Staphylococcus vaccine: why have candidates failed and what is the next step?15
Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs14
Pneumococcal conjugate vaccines in older adults and immunocompromised individuals14
Mapping and ranking outcomes for the evaluation of seasonal influenza vaccine efficacy and effectiveness: a delphi study14
Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine14
Cost-effectiveness of maternal vaccination against respiratory syncytial virus in Hong Kong: a decision-analytical analysis14
A journey worth taking: global eradication of measles, rubella and congenital rubella syndrome14
Public health impact and return on investment of the pediatric immunization program in Poland14
Changes in vaccine administration trends across the life-course during the COVID-19 pandemic in the United States: a claims database study14
Exploring determinants of vaccine hesitancy among healthcare professionals: a systematic literature review14
Have mRNA vaccines sentenced DNA vaccines to death?13
Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era13
Health behaviors are largely not predictive of adverse events following influenza vaccination13
Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations13
Options for the development of a bivalent vaccine against SARS-CoV-2 and influenza13
Effectiveness of the autumnal COVID-19 vaccine dose during the winter and summer waves of the 2023/24 season in Spain13
COVID-19 and vaccination: myths vs science13
Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model13
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice13
Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses13
Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit–cost analysis13
Correction13
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older13
Pneumococcal vaccination coverage among US adults enrolled in Medicaid and newly diagnosed with underlying medical conditions12
Reverse engineering approach: a step towards a new era of vaccinology with special reference to Salmonella12
Vaccines against SARS-CoV-2 variants and future pandemics12
PPSV-23 recommendation and vaccination coverage in China: a cross-sectional survey among healthcare workers, older adults and chronic disease patients12
Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution12
Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines12
Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis12
Subolesin: a 20-year path from discovery to an effective tick vaccine12
0.17699790000916